• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Patterson Companies Announces Leadership Transition

    10/13/22 9:00:00 AM ET
    $PDCO
    Medical Specialities
    Health Care
    Get the next $PDCO alert in real time by email

    Don Zurbay Appointed President and CEO

    Kevin Barry Appointed Interim Chief Financial Officer

    Reaffirms Fiscal 2023 Earnings Guidance

    Patterson Companies, Inc. (NASDAQ:PDCO) today announced that its Board of Directors has appointed Don Zurbay, most recently Chief Financial Officer, as President and Chief Executive Officer. Mr. Zurbay succeeds Mark Walchirk who resigned following the Board's investigation and determination that he violated company policy and demonstrated poor judgment regarding an encounter with an employee. The conduct did not relate to the company's operations or the integrity of the company's financial statements. Mr. Zurbay has also been elected to the Board. Kevin Barry, currently Vice President, Finance & Corporate Controller, has been appointed Interim Chief Financial Officer.

    John D. Buck, Chairman of the Patterson Board, said, "Patterson is committed to cultivating a people-first culture where every employee is treated with respect and those standards apply to every member of the organization. Immediately upon becoming aware of the allegation, the independent directors conducted a comprehensive investigation with the support of independent, outside legal counsel and determined that Mark could not remain in his leadership position.

    "Don has been an instrumental member of our leadership team since joining Patterson in 2018, helping to drive profitable growth in our Dental and Animal Health businesses through improved operating performance, build a high-performance culture, and generate value for our shareholders. We have the utmost confidence that Don, Kevin, and the rest of the Patterson leadership team will continue to execute our proven strategy of continuously enhancing Patterson's value proposition while driving financial and operating performance improvement."

    "I'm honored to lead the talented and experienced Patterson team as we focus on creating value for our customers and shareholders," said Mr. Zurbay. "I'm excited to continue to work closely with the Board and the rest of the management team in my new role to build on our strong momentum and capitalize on the many opportunities ahead."

    Fiscal Year 2023 Guidance

    Patterson reaffirmed its previously provided fiscal 2023 earnings guidance, which is provided on both a GAAP and non-GAAP adjusted basis:

    • GAAP earnings are expected to be in the range of $1.96 to $2.06 per diluted share.
    • Non-GAAP adjusted earnings are expected to be in the range of $2.25 to $2.35 per diluted share.
    • Our non-GAAP adjusted earnings guidance excludes the after-tax impact of:
      • Deal amortization expenses of approximately $28.5 million ($0.29 per diluted share).

    Our guidance reflects the strength of our business and competitive positioning, as well as our expectations for the North American and international end markets in which we operate, which we expect to be affected by inflationary trends, higher interest rates and a potential slow-down in the broader economy. Beyond macroeconomic and geopolitical uncertainty, our guidance further assumes that there are no material adverse developments associated with the pandemic.

    About Patterson Companies Inc.

    Patterson Companies Inc. (NASDAQ:PDCO) connects dental and animal health customers in North America and the U.K. to the latest products, technologies, services and innovative business solutions that enable operational and professional success. Our comprehensive portfolio, distribution network and supply chain are equaled only by our dedicated, knowledgeable people who deliver unrivaled expertise and unmatched customer service and support. Learn more: pattersoncompanies.com

    This press release contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding future financial performance, and the objectives and expectations of management. Forward-looking statements often include words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "seeks" or words of similar meaning, or future or conditional verbs, such as "will," "should," "could" or "may." Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Any number of factors could affect our actual results and cause such results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the following: the COVID-19 pandemic and measures taken in response thereto; uncertain macro-economic conditions, including inflationary pressures; our dependence on relationships with sales representatives and service technicians to retain customers and develop business; potential disruption of distribution capabilities, including service issues with third-party shippers; our dependence on suppliers to manufacture and supply substantially all of the products we sell; the risk of the products we sell becoming obsolete or containing undetected errors; adverse changes in supplier rebates or other purchasing incentives; the risk that private label sales could adversely affect our relationships with suppliers; our dependence on positive perceptions of Patterson's reputation; risks inherent in acquiring and disposing of assets or other businesses and the risks inherent in integrating acquired businesses; our ability to comply with restrictive covenants in our credit agreement; turnover or loss of key personnel or highly skilled employees; the risk that our governing documents and Minnesota law may discourage takeovers and business combinations; risks related to climate change; the effects of the highly competitive and consolidating dental and animal health supply markets in which we compete; exposure to the risks of the animal production business, including changing consumer demand, the cyclical livestock market, and other factors outside our control, and the risks of the companion animal business, including the possibility of disease adversely affecting the pet population; risks from the formation or expansion of GPOs, provider networks and buying groups that may shift purchasing decisions and place us at a competitive disadvantage; increases in over-the-counter sales and e-commerce options for companion animal products or sales of companion animal products from non-veterinarian sources; change and uncertainty in the health care industry; failure to comply with existing or future U.S. or foreign laws and regulations including those governing the distribution of pharmaceuticals and controlled substances; failure to comply with health care fraud or other laws and regulations; litigation risks, including the diversion of management's attention, the cost of defending against such actions, the possibility of damage awards or settlements, fines or penalties, or equitable remedies (including but not limited to the revocation of or non-renewal of licenses) and inherent uncertainty; failure to comply with evolving data privacy laws and regulations; tax legislation; the risks inherent in international operations, including currency fluctuations; and risks associated with information systems, software products and cyber-security attacks. The order in which these factors appear should not be construed to indicate their relative importance or priority. We caution that these factors may not be exhaustive, accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. You should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, ("Risk Factors") in our most recent Form 10-K and information which may be contained in our other filings with the U.S. Securities and Exchange Commission, or SEC, when reviewing any forward-looking statement. Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider the foregoing list, or the risks identified in our SEC filings, to be a complete discussion of all potential risks or uncertainties. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We do not undertake any obligation to release publicly any revisions to any forward-looking statements whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221013005424/en/

    Get the next $PDCO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PDCO

    DatePrice TargetRatingAnalyst
    12/4/2024$23.00Neutral
    Mizuho
    2/29/2024$34.00 → $28.00Overweight → Neutral
    Piper Sandler
    2/26/2024$36.00Outperform
    Leerink Partners
    5/13/2022$36.00Outperform
    Credit Suisse
    3/3/2022$30.00 → $32.00Equal-Weight
    Morgan Stanley
    1/31/2022$30.00Equal-Weight
    Morgan Stanley
    10/1/2021$38.00Outperform
    Credit Suisse
    More analyst ratings

    $PDCO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Patterson Companies Inc.

      15-12G - PATTERSON COMPANIES, INC. (0000891024) (Filer)

      4/28/25 10:30:38 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by Patterson Companies Inc.

      8-K - PATTERSON COMPANIES, INC. (0000891024) (Filer)

      4/22/25 9:00:17 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Patterson Companies Inc.

      S-8 POS - PATTERSON COMPANIES, INC. (0000891024) (Filer)

      4/17/25 9:23:38 AM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sterling Infrastructure Set to Join S&P SmallCap 600

      NEW YORK, April 14, 2025 /PRNewswire/ -- Sterling Infrastructure Inc. (NASD: STRL) will replace Patterson Companies Inc. (NASD: PDCO) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 17. Patient Square Capital is acquiring Patterson Companies in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 17, 2025 S&P SmallCap 600 Addition Sterling Infrastructure STRL Industrials April 17, 2025 S&P SmallCap 600 Deletion Patterson Companies PDCO Health Care Fo

      4/14/25 6:43:00 PM ET
      $PDCO
      $SPGI
      $STRL
      Medical Specialities
      Health Care
      Finance: Consumer Services
      Finance
    • Patterson Companies, Inc. Shareholders Approve Acquisition by Patient Square Capital

      Patterson Companies, Inc. (NASDAQ:PDCO), a value-added specialty distributor serving the U.S. and Canadian dental supply markets and the U.S., Canadian and U.K. animal health supply markets, today announced that its shareholders approved at a special meeting the acquisition of Patterson by Patient Square Capital, a dedicated health care investment firm. Don Zurbay, Patterson's President and Chief Executive Officer, said, "I would like to express my gratitude to the Patterson shareholders for their support today, and throughout this transaction process. The Patterson team is excited about this partnership with Patient Square Capital and beginning our next chapter as a private company. We be

      4/1/25 1:00:00 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies Reports Fiscal 2025 Third Quarter Operating Results

      Third quarter reported net sales decreased 2.7 percent year-over-year to $1.57 billion, and internal sales decreased 2.4 percent. Delivered third quarter GAAP earnings of $0.35 per diluted share and adjusted earnings1 of $0.43 per diluted share; both GAAP and adjusted earnings1 were negatively impacted by the cybersecurity attack on Change Healthcare compared to the prior year. Returned $119.2 million to shareholders in the form of cash dividends and share repurchases through the first nine months of fiscal 2025. Patterson Companies, Inc. (NASDAQ:PDCO) today reported operating results for its fiscal 2025 third quarter ended January 25, 2025. "As we continue to progress toward cl

      2/26/25 4:30:00 PM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tomczik Pamela J returned 7,820 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - PATTERSON COMPANIES, INC. (0000891024) (Issuer)

      4/17/25 2:15:41 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Director Schrimsher Neil A returned 48,788 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - PATTERSON COMPANIES, INC. (0000891024) (Issuer)

      4/17/25 2:08:45 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Director Mckoy Philip returned 18,114 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - PATTERSON COMPANIES, INC. (0000891024) (Issuer)

      4/17/25 2:06:32 PM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Patterson Companies with a new price target

      Mizuho initiated coverage of Patterson Companies with a rating of Neutral and set a new price target of $23.00

      12/4/24 7:46:30 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Patterson Companies from Overweight to Neutral and set a new price target of $28.00 from $34.00 previously

      2/29/24 6:36:04 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • Leerink Partners initiated coverage on Patterson Companies with a new price target

      Leerink Partners initiated coverage of Patterson Companies with a rating of Outperform and set a new price target of $36.00

      2/26/24 8:10:56 AM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Financials

    Live finance-specific insights

    See more
    • Patterson Companies Reports Fiscal 2025 Third Quarter Operating Results

      Third quarter reported net sales decreased 2.7 percent year-over-year to $1.57 billion, and internal sales decreased 2.4 percent. Delivered third quarter GAAP earnings of $0.35 per diluted share and adjusted earnings1 of $0.43 per diluted share; both GAAP and adjusted earnings1 were negatively impacted by the cybersecurity attack on Change Healthcare compared to the prior year. Returned $119.2 million to shareholders in the form of cash dividends and share repurchases through the first nine months of fiscal 2025. Patterson Companies, Inc. (NASDAQ:PDCO) today reported operating results for its fiscal 2025 third quarter ended January 25, 2025. "As we continue to progress toward cl

      2/26/25 4:30:00 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies Reports Fiscal 2025 Second Quarter Operating Results

      Second quarter reported net sales increased 1.3 percent year-over-year to $1.67 billion, and internal sales increased 0.6 percent. Delivered second quarter GAAP earnings of $0.30 per diluted share and adjusted earnings1 of $0.47 per diluted share; both GAAP and adjusted earnings1 were negatively impacted by the cybersecurity attack on Change Healthcare compared to the prior year. Returned $96.2 million to shareholders in the form of cash dividends and share repurchases through the first six months of fiscal 2025. Revises fiscal 2025 GAAP earnings guidance range to $1.83 to $1.93 per diluted share and adjusted earnings1 guidance range to $2.25 to $2.35 per diluted share. Company

      12/5/24 7:00:00 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies Fiscal 2025 Second Quarter Conference Call Scheduled for Thursday, December 5, 2024

      Patterson Companies (NASDAQ:PDCO) today announced that it will hold its fiscal 2025 second-quarter conference call on Thursday, December 5, 2024, at 7:30 a.m. CT (8:30 a.m. ET). The company's earnings release will be issued that morning before the market opens. To access the live webcast, go to the investor relations section of the company's website, www.PattersonCompanies.com. An audio replay of the fiscal 2025 second-quarter conference call will also be available for one week. To access the audio replay, please pre-register at https://registrations.events/direct/Q4I672812531 to receive a unique access code to access and listen to the audio playback. About Patterson Companies Inc. Pa

      11/27/24 7:19:00 PM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Leadership Updates

    Live Leadership Updates

    See more
    • Sterling Infrastructure Set to Join S&P SmallCap 600

      NEW YORK, April 14, 2025 /PRNewswire/ -- Sterling Infrastructure Inc. (NASD: STRL) will replace Patterson Companies Inc. (NASD: PDCO) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 17. Patient Square Capital is acquiring Patterson Companies in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 17, 2025 S&P SmallCap 600 Addition Sterling Infrastructure STRL Industrials April 17, 2025 S&P SmallCap 600 Deletion Patterson Companies PDCO Health Care Fo

      4/14/25 6:43:00 PM ET
      $PDCO
      $SPGI
      $STRL
      Medical Specialities
      Health Care
      Finance: Consumer Services
      Finance
    • Patterson Companies Announces Dental Leadership Appointment

      Kristin Dietzler Named Dental President Patterson Companies Inc. (NASDAQ:PDCO) announced the appointment of Kristin Dietzler as Patterson Dental's North American president. Dietzler brings extensive expertise in adjacent healthcare companies with a proven track record of success in optimizing results. She will report to Kevin Pohlman, chief operating officer of Patterson Companies, and she will be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241023782217/en/Kristin Dietzler Named Patterson Dental President (Photo: Business Wire) Dietzler joins Patterson Dental with nearly 30

      10/23/24 6:00:00 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies Announces Dental Leadership Transition

      Patterson Companies, Inc. (NASDAQ:PDCO) today announced that it has initiated a search for a new leader for its Dental segment. Tim Rogan, who has served as President of Patterson Dental since 2021, has stepped down from his role, effective immediately, and agreed to serve as an advisor to the Company in the short term to facilitate a smooth transition. The Dental segment will continue to report to Chief Operating Officer, Kevin Pohlman. "Our dental business has made significant progress to further enhance our value proposition and differentiate Patterson as the partner of choice for our customers. After careful consideration, we determined that a leadership transition will best position

      5/10/24 7:00:00 AM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Patterson Companies Inc. (Amendment)

      SC 13G/A - PATTERSON COMPANIES, INC. (0000891024) (Subject)

      2/13/24 5:12:03 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Patterson Companies Inc. (Amendment)

      SC 13G/A - PATTERSON COMPANIES, INC. (0000891024) (Subject)

      12/8/23 4:16:31 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Patterson Companies Inc. (Amendment)

      SC 13G/A - PATTERSON COMPANIES, INC. (0000891024) (Subject)

      2/14/23 12:37:55 PM ET
      $PDCO
      Medical Specialities
      Health Care